Abrocitinib (PF-04965842) (Synonyms: PF-04965842) |
| رقم الكتالوجGC32023 |
أبروسيتينيب (PF-04965842) (PF-04965842) هو مثبط فعال وفعال عن طريق الفم وانتقائي JAK1 ، مع IC50s من 29 و 803 نانومتر لـ JAK1 و JAK2 ، على التوالي.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1622902-68-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Abrocitinib (PF-04965842) is a orally active and selective Janus kinase (JAK) inhibitor with IC50 values of 29nM and 803nM for JAK1 and JAK2, respectively[1]. Abrocitinib approved to treat atopic dermatitis (AD) by the Food and Drug Administration (FDA)[2]. Abrocitinib also possess anti-inflammtation and can be used to treat fibrosis and traumatic brain injury[3][6].
In vitro, Abrocitinib (1µM) incubated hepatic stellate cell (HSC)-T6 for 24 hours significant decreased in the RNA levels of Col1a1, Jak1 and Acta2 and the protein levels of type I alpha 1 chain (COL1A1), JAK1, and actin alpha 2 (ACTA2). The Abrocitinib treated group also showed a significant decrease in the proportion of apoptotic cells[3]. Peripheral blood mononuclear cells were isolated and stimulated with tuberculosis (TB) antigen and Abrocitinib (0, 0.75, and 1.5µM) for 24 hours. Abrocitinib significantly reduced TB antigen-dependent T-cell activation and subsequently reduced the IFN-production[4]. Abrocitinib (0.1–1000mM) incubated with 0.3mg/mL microsomal protein HLM-103 at 37℃ revealed that the primary enzymes involved in Abrocitinib metabolism were CYP2C19, CYP2C9, CYP3A4, and CYP2B6. The enzyme kinetic parameters for the formation of major metabolites M1, M2/M3, and M4 were determined using Michaelis-Menten substrate inhibition modeling[5].
In vivo, Abrocitinib (40mg/kg of body weight, daily) orally administrated for 10 days into rat models of post-liver transplantation (LT) liver fibrosis decreased the stage of liver fibrosis and the levels of COL1A1 and ACTA2[3]. Abrocitinib (10mg/kg) administrated via the intragastric route into traumatic brain injury (TBI) mouse models could ameliorate neuroinflammation and exert a neuroprotective effect via Inhibiting the JAK1/STAT1/NF-κB Pathway. Compared to the TBI group, the Abrocitinib treatment group showed less trauma lesions, better neurological function, less blood-brain barrier (BBB) leakagea and improved intracranial blood flow[6]. Sprague-Dawley rats orally administrated Abrocitinib (20mg/kg) 30min after orally given amitriptyline (15mg/kg) and fluoxetine (5mg/kg), two commonly used antidepressants that inhibit the activities of CYP2C19 and CYP3A4. The results indicated that amitriptyline and fluoxetine could significantly increase the plasma concentration of Abrocitinib in rats. Dose adjustment of Abrocitinib may be required when it is combined with amitriptyline or fluoxetine[7].
References:
[1] Nicole Ramsey N, Wajiha Kazmi W, Matthew Phelan M,et al. JAK1 inhibition with Abrocitinib (PF-04965842) decreases allergen-specific basophil and T-cell activation in pediatric peanut allergy. J Allergy Clin Immunol Glob. 2023 Aug;2(3):100103.
[2] McLornan D P, Pope J E, Gotlib J, Harrison C N. Current and future status of JAK inhibitors. Lancet. 2021 Aug 28;398(10302):803-816.
[3] Si Z Y, Zhao S Q, Zhang Z X, et al. Bone marrow mesenchymal stem cells alleviate liver fibrosis after rat liver transplantation through JAK1/STAT5 pathway. Stem Cell Res Ther. 2025 May 1;16(1):217.
[4] Li Y T, Tan X, Nie S, et al. Abrocitinib interferes with the performance of T-SPOT.TB assay for latent tuberculosis reactivation: An in vitro study. J Am Acad Dermatol. 2025 May;92(5):1124-1125.
[5]Bauman J N, Doran A C, Ahmad A K, et al. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans. Drug Metab Dispos. 2022 Aug;50(8):1106-1118.
[6] Li T, Li L, Peng R L, et al. Abrocitinib (PF-04965842) Attenuates Microglia-Mediated Neuroinflammation after Traumatic Brain Injury via Inhibiting the JAK1/STAT1/NF-κB Pathway. Cells. 2022 Nov 13;11(22):3588.
[7] Chen L G, Chen X H, Liu J P, et al. Effects of two commonly used antidepressants amitriptyline and fluoxetine on the pharmacokinetics of abrocitinib in rats. Chem Biol Interact. 2024 Jul 1:397:111041.
| Kinase experiment [1]: | |
Preparation Method | Abrocitinib (0.1–1000mM) was incubated in 100mM potassium phosphate buffer (pH 7.4) containing 3mM MgCl2 and 0.3mg/mL microsomal protein HLM-103 at 37℃. Reactions were initiated with NADPH (1.2mM) immediately followed by substrate and terminated after 15 minutes by quenching aliquots of the incubation mixture with acetonitrile-containing internal standard (10ng/mL). Samples were centrifuged (1700g) for 10 minutes, and 100mL of supernatant was transferred to a 96 deep-well plate. The supernatants were dried down under a stream of nitrogen and reconstituted in 100mL of 90% water/10% acetonitrile. Incubations for enzyme kinetic determination were conducted in triplicate. |
Reaction Conditions | 0.1–1000mM; 15min |
Applications | The metabolism of Abrocitinib in human liver microsomes mainly occurs through CYP2C19, CYP2C9, CYP3A4 and CYP2B6. Enzyme kinetic parameters and intrinsic clearance values for the formation of Metabolite 1, Metabolite2/Metabolite3, and Metabolite 4 from Abrocitinib metabolism in human liver microsomes were determined (e.g. for Metabolite 1, Km, Michaelis constant = 143 ± 20mM; Vmax, maximum rate of metabolism=26.7 ± 2.2pmol/min per mg). |
| Cell experiment [2]: | |
Cell lines | Mouse BV2 microglial cells |
Preparation Method | Mouse BV2 microglial cells were exposed to LPS to mimic cerebral neuroinflammation after traumatic brain injury (TBI) in vitro. To evaluate its effects on microglial polarization, Abrocitinib (100nM, 500nM, or 1µM) was added to the culture medium for the management of LPS (10µg/mL). The treated BV2 cells were collected after 6h of LPS irritation for further immunofluorescence (IF) staining. |
Reaction Conditions | 100nM, 500nM, or 1µM; 6h |
Applications | Abrocitinib treatment was shown to reduce the pro-inflammatory M1 microglia phenotype and shift microglial polarization toward the anti-inflammatory M2 phenotype. The WB and IHC results showed that Abrocitinib played a neuroprotective role by restraining JAK1/STAT1/NF-κB levels after TBI. |
| Animal experiment [3]: | |
Animal models | Sprague–Dawley (SD) rats |
Preparation Method | The animals were randomly divided into the Sham group, liver transplantation (LT) group, LT+BMSC group, LT+Abrocitinib group, with 6 animals in each group. The LT group was subjected to a transplantation of the liver with a cold storage time of 4h. The LT+BMSC group received 5×106 BMSCs by injection through the portal vein after blood flow opening during LT. In addition to LT, the LT+Abrocitinib group received Abrocitinib (40mg/kg of body weight, per os, daily) for 10 days. |
Dosage form | 40mg/kg; per os; daily for 10 days |
Applications | LT+Abrocitinib group showed reduced hepatic lobular structural disorder, fibrous connective tissue proliferation, and inflammatory cell infiltration in the HE staining camparing to LT group. LT+Abrocitinib group also showed a significant decrease in the RNA levels of Col1a1, Jak1, Acta2, and Casp3. The protein levels of COL1A1, JAK1, ACTA2, and CASP3 were significantly reduced in the LT+Abrocitinib group. |
References: | |
| Cas No. | 1622902-68-4 | SDF | |
| المرادفات | PF-04965842 | ||
| Canonical SMILES | CN([C@H]1C[C@@H](NS(CCC)(=O)=O)C1)C2=C3C(NC=C3)=NC=N2 | ||
| Formula | C14H21N5O2S | M.Wt | 323.41 |
| الذوبان | DMSO : 125 mg/mL (386.51 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0921 mL | 15.4603 mL | 30.9205 mL |
| 5 mM | 618.4 μL | 3.0921 mL | 6.1841 mL |
| 10 mM | 309.2 μL | 1.546 mL | 3.0921 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *